找化学品上960化工网!
960化工网

洛匹那韦 | 192725-17-0

洛匹那韦
Lopinavir
192725-17-0
C37H48N4O5
628.8008
如需查看该化合物的详细结构式,mol文件,smile,InChi 请点击:洛匹那韦结构式
92727
洛匹那韦价格
简介
Lopinavir (ABT-378) 是一种高效、选择性肽模拟 HIV-1 蛋白酶 (HIV-1 protease) 的抑制剂,对野生型和突变型 HIV 蛋白酶的抑制 Kis 值为 1.3 到 3.6 pM。Lopinavir 通过阻止 HIV-1 的成熟而起作用,从而阻断其感染性。Lopinavir 也是 SARS-CoV 3CLpro 的抑制剂,IC50 为 14.2 μM。
名称和标识符
MDL MFCD22373646
InChIKey KJHKTHWMRKYKJE-SUGCFTRWSA-N
Inchi 1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
SMILES O([H])[C@]([H])([C@]([H])(C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C(C([H])([H])OC1C(C([H])([H])[H])=C([H])C([H])=C([H])C=1C([H])([H])[H])=O)C([H])([H])[C@]([H])(C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C([C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N1C(N([H])C([H])([H])C([H])([H])C1([H])[H])=O)=O
别名信息
- 中文别名 -
  • 洛匹那韦
  • 咯匹那韦
  • 罗比那韦
  • 洛匹那韦 EP标准品
  • 洛匹那韦 USP标准品
  • 洛匹那韦 标准品
  • 洛匹那韦峰鉴别 EP标准品
  • 洛匹那韦系统适用性 EP标准品
  • 三甲硅烷基丙炔酸盐
  • (2S)-N-[(2R,4S,5S)-5-[[2-(2,6-二甲基苯氧基)乙酰]氨基]-4-羟基-1,6-二苯基-己-2-基]-3-甲基-2-(2-氧代-1,3-二氮杂环己-1-基)丁酰胺
  • 罗平拉韦
  • 洛吡那韦
  • 洛匹那韦 LOPINAVIR
  • 洛匹那韦(标准品)
  • 洛匹那韦, HIV 蛋白酶抑制剂
  • 洛匹那韦(对照品)
- 英文别名 -
  • Lopinavir
  • (2S)-N-[(2R,4S,5S)-5-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenyl-hexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
  • (S)-N-((2R,4S,5S)-5-(2-(2,6-Dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenyl-hexn-2-yl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide
  • N-((2S,4S,5S)-5-(2-(2,6-Dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide
  • ABT 378
  • ABT-378
  • Aluviran
  • Koletr
  • Koletra
  • (αS)-N-[(1S,3S,4S)-4-[[(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-
  • A 157378.0
  • ABT-378 whatsapp
  • Lopinavir (350 mg)
  • Lopinavir (ABT-378)
  • Lopinavir for system suitability
  • Kaletra
  • LPV
  • (alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
  • A 157378
  • 2494G1JF75
  • N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
  • DSSTox_RID_81
  • LOPINAVIR [EP MONOGRAPH]
  • MLS004774152
  • (alphaS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
  • LOPINAVIR [MI]
  • LOPINAVIR (EP MONOGRAPH)
  • 1mui
  • LOPINAVIR COMPONENT OF KALETRA
  • LOPINAVIR [WHO-IP]
  • AB01274785-01
  • Tox21_112204
  • A813594
  • 2rkg
  • LOPINAVIR [EMA EPAR]
  • AB01274785_02
  • NCGC00164576-03
  • DTXSID8046456
  • CAS-192725-17-0
  • (2S)-N-[(1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide
  • D01425
  • J05AE06
  • ABT378
  • (2S)-N-[(2R,4S,5S)-5-[[2-(2,6-DIMETHYLPHENOXY)ACETYL]AMINO]-4-HYDROXY-1,6-DIPHENYL-HEXAN-2-YL]-3-METHYL-2-(2-OXO-1,3-DIAZINAN-1-YL)BUTANAMIDE
  • Lopinavir, Bio-X
  • GTPL11504
  • LOPINAVIR (USP MONOGRAPH)
  • LOPINAVIR (MART.)
  • (S)-N-((2S,4S,5S)-5-(2-(2,6-dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide
  • 2q5k
  • DB01601
  • AKOS025243115
  • NCGC00164576-02
  • KALETRA COMPONENT LOPINAVIR
  • BRD-K99451608-001-02-4
  • LOPINAVIR [USP MONOGRAPH]
  • (alphaS)-Tetrahydro-N-[(alphaS)-alpha-[(2S,3S)-2-hydroxy-4-phenyl-3-[2-(2,6-xylyloxy)acetamido]butyl]phenethyl]-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
  • HSDB 8138
  • (2S)-N-((1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide
  • 1(2H)-Pyrimidineacetamide, N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphaS)-
  • MFCD22628840
  • 4l1a
  • NCGC00164576-01
  • 192725-17-0
  • J-521653
  • CHEBI:31781
  • Lopinavirum
  • Kaletra (LPV+RTV)
  • 1(2H)-pyrimidineacetamide, N-[(1S,3S,4S)-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)-
  • LOPINAVIR [VANDF]
  • HY-14588
  • 1(2H)-Pyrimidineacetamide, N-[4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, [1S-[1R*(R*),3R*,4R*]]-
  • Lopinavir-
  • LOPINAVIR (USP-RS)
  • SR-01000931910
  • LOPINAVIR [JAN]
  • LOPINAVIR [USAN]
  • s1380
  • EN300-7402887
  • Tox21_112204_1
  • C37H48N4O5
  • CS-2077
  • (2S)-N-[(1S,3S,4S)-1-benzyl-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-pentyl]-3-methyl-2-(2-oxohexahydropyrimidin-1-yl)butanamide
  • 3ogq
  • RS-346
  • Q422585
  • LOPINAVIR [MART.]
  • KJHKTHWMRKYKJE-SUGCFTRWSA-N
  • (2S)-N-[(2S,4S,5S)-5-{[(2,6-dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide
  • (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
  • L0377
  • BCP9000857
  • BDBM50180655
  • SR-01000931910-2
  • (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
  • LOPINAVIR [USP-RS]
  • SW219767-1
  • KS-1436
  • 2qhc
  • ABT-378
  • LOPINAVIR
  • Lopinavir 100 microg/mL in Acetonitrile
  • A-157378-0
  • Lopinavir, (s-(2s,4s,5s))-
  • Z2235801862
  • MLS006011206
  • EX-A4008
  • LPV & AAG
  • LOPINAVIR [ORANGE BOOK]
  • LOPINAVIR [INN]
  • DTXCID6026456
  • NCGC00164576-04
  • 2o4s
  • NS00008581
  • A-1573780
  • MLS003915624
  • ABT-378/r
  • (1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
  • 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
  • BL164636
  • CHEMBL729
  • CCG-270285
  • SCHEMBL21775
  • 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-.alpha.-(1-methylethyl)-2-oxo-, (aS)-
  • 2rkf
  • LOPINAVIR [WHO-DD]
  • A-157378.0
  • AIDS032937
  • Lopinavir [USAN:USP:INN:BAN]
  • LOPINAVIRUM [WHO-IP LATIN]
  • Lopinavir & PLGA
  • Lopinavir & alpha1-acid glycoprotein
  • (1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-DIMETHYLPHENOXY)ACETYL)AMINO)-3-HYDROXY-5-PHENYL-1-(PHENYLMETHYL)PENTYL)TETRAHYDRO-.ALPHA.-(1-METHYLETHYL)-2-OXO-1(2H)-PYRIMIDINEACETAMIDE
  • UNII-2494G1JF75
  • Lopinavir (JAN/USP/INN)
  • SMR002529581
  • BCPP000184
  • HB7108
物化性质
实验特性
LogP 4.39310
PSA 120.00000
折射率 1.577
沸点 924.1°C at 760 mmHg
熔点 113-118°C
闪点 512.7±34.3 °C
溶解度 DMSO: soluble20mg/mL, clear
颜色与性状 结晶固体
稳定性 Hygroscopic
光学活性 [α]/D -20 to -27°, c = 0.4 in methanol
密度 3.1800
计算特性
精确分子量 628.36200
氢键供体数量 4
氢键受体数量 5
可旋转化学键数量 15
同位素质量 628.362
重原子数量 46
复杂度 940
同位素原子数量 0
确定原子立构中心数量 0
不确定原子立构中心数量 4
确定化学键立构中心数量 0
不确定化学键立构中心数量 0
共价键单元数量 1
疏水参数计算参考值(XlogP) 5.9
拓扑分子极性表面积 120
相关文献
专业数据库参考
PubChemId 92727
参考资料
Reaxys RN
化合物详情(旧版)

物理化学性质

密度: 1.163g/cm3 
沸点: 924.1°C at 760 mmHg 
闪点: 512.7°C 
蒸汽压: 0mmHg at 25°C 
白色至黄褐色粉末,可以任何比例溶于甲醇和乙醇,可溶于异丙醇,不溶于水

产品用途

是一种HIV蛋白酶抑制剂

应用领域

抗爱滋新药,该药品将用于与其他抗逆转录病毒药物联合用药,治疗HIV感染

上下游产品信息




化学品安全说明书(MSDS)



储运特性





扩展阅读
洛匹那韦英文资料: http://www.globalchemtrade.com/cas/cas_192725-17-0.shtml 洛匹那韦供应商: http://www.chem960.com/supplier/suppliers_of_192725-17-0.shtml
960化工网为您提供洛匹那韦专业化合物百科信息,包括中文名,英文名,分子式,分子量,以及该化合物的CasNo.:192725-17-0,和相关理化性质;并提供了优质生产厂家信息包括厂家名称和联系方式等;| WAP 版:192725-17-0
平台客服 平台客服

平台在线客服